Aplagon is a biotech company pioneering the development of innovative, first-in-class therapies for thromboinflammatory diseases, which are driven by the interplay of thrombosis, inflammation, and vascular injury. The company focuses on advanced treatments from concept through early clinical development.
Aplagon's programs target critical unmet medical needs in conditions such as Arteriovenous Fistula (AVF) maturation failure for hemodialysis and Critical Limb Ischemia (CLI), both of which have limited or no effective therapies. Its lead candidate, APAC, is a novel bioconjugate therapy designed to improve vascular outcomes by uniquely combining antiplatelet, anticoagulant, and anti-inflammatory effects. APAC is currently being evaluated in clinical trials, to address significant patient needs and improve outcomes in these challenging thromboinflammatory conditions.
